Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials

Data from recent clinical trials utilizing bevacizumab or other anti-VEGF agents in patients with metastatic colorectal cancer (mCRC) show improvements in progression-free survival (PFS) but modest, if any, improvements in overall survival (OS). Despite modest improvements, use of bevacizumab beyond...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Patel, Sukeshi R., Karnad, Anand B., Ketchum, Norma S., Pollock, Brad H., Sarantopoulos, John, Weitman, Steven, Mahalingam, Devalingam
Format: Artigo
Idioma:Inglês
Publicat: Pioneer Bioscience Publishing Company 2014
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3999623/
https://ncbi.nlm.nih.gov/pubmed/24772337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2014.002
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars